REGENERON PHARMACEUTICALS INC. - COMMON STOCK

716.90

13-January-25 16:45:00

15 minutes delayed

Stocks

+20.02

+2.87%

Today's range

666.25 - 717.37

ISIN

N/A

Source

NASDAQ

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Nov 2024 09:45:40 By NetDania Notify
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Nov 2024 09:45:06 By NetDania Notify
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

15 Nov 2024 00:59:51 By Nasdaq GlobeNewswire
NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

14 Nov 2024 15:47:28 By NetDania Notify
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

13 Nov 2024 07:00:25 By Nasdaq GlobeNewswire
Regeneron Announces Investor Conference Presentations

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

06 Nov 2024 01:00:00 By Nasdaq GlobeNewswire
Regeneron Reports Third Quarter 2024 Financial and Operating Results

31 Oct 2024 06:30:01 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

24 Oct 2024 08:00:04 By Nasdaq GlobeNewswire
Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18 Oct 2024 17:05:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27 Sep 2024 09:35:08 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27 Sep 2024 07:00:04 By Nasdaq GlobeNewswire
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26 Sep 2024 16:05:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

20 Sep 2024 07:45:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

13 Sep 2024 12:15:28 By Nasdaq GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile

11 Sep 2024 07:00:46 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

11 Sep 2024 01:04:00 By Nasdaq GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

11 Sep 2024 00:59:00 By Nasdaq GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

09 Sep 2024 17:00:00 By Nasdaq GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO

09 Sep 2024 07:00:17 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.